TABLE 3.

AEs after multiple doses of POS i.v. 200/300 mg followed by multiple doses of twice-daily POS oral suspension 400 mg (cohorts 1 and 2)^a

AE type	No. (%) of subjects with indicated AEb
	Cohort 1: POS i.v. 200 mg q.d.c (n = 21)	Cohort 2: POS i.v. 300 mg q.d. (n = 24)
Any treatment-emergent AE	20 (95)	24 (100)
Treatment-related AE	3 (14)	8 (33)
SAEd	4 (19)	9 (38)
Treatment-related SAE	0	1 (4)
AE leading to study drug discontinuation	4 (19)	7 (29)
Discontinuation during POS i.v.	3	5
Discontinuation during POS oral suspension	1	2
SAE leading to study drug discontinuation	1 (5)	2 (8)
Death	1 (5)	3 (13)

^aAE, adverse event; POS, posaconazole; i.v., intravenous.

^bAll subjects received POS i.v. 200 or 300 mg on days 1 to 14 followed by 14 days of twice-daily POS oral suspension 400 mg.

^cq.d., once daily

^dSAE, serious adverse event.